

Notice of Allowability	Application No.	Applicant(s)	Applicant(s)	
	09/555,906	DRIFU, KATY	DRIEU, KATY	
	Examiner	Art Unit		
	Dr. Kailash C. Srivastava	1651		
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT Re of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED ir or other appropriate commu GHTS. This application is s	n this application. If not include unication will be mailed in due o	d course. THIS	
 This communication is responsive to <u>RCE Filed 09/15/2003</u> The allowed claim(s) is/are <u>14-24</u>. The drawings filed on are accepted by the Examinet Acknowledgment is made of a claim for foreign priority und a) All b) Some* c) None of the: Certified copies of the priority documents have Copies of the certified copies of the priority documents have Copies of the certified copies of the priority documents have 	r. er 35 U.S.C. § 119(a)-(d) or been received. been received in Applicatio	on No	on from the	
* Certified copies not received: 5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). (a) The translation of the foreign language provisional application has been received. 6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE				
7. A SUBSTITUTE OATH OR DECLARATION must be subm			OTICE OF	
 8. CORRECTED DRAWINGS must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No 				
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet.				
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.				
Attachment(s) 1☐ Notice of References Cited (PTO-892) 3☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 5☑ Information Disclosure Statements (PTO-1449), Paper No 6☑ Examiner's Amendment/Comment 7☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 7☐ Other				

Examiner's Comments and Amendment

- 1. A Request for Continued Examination under 37 CFR §1.114, including the fee set forth in 37 CFR §1.17(e), was filed in this application after Decision on Appeal by the Board of Patent Appeals and Interferences under 35 U.S.C.§134. Since this application is eligible for continued examination under 37 CFR §1.114 and the fee set forth in 37 CFR §1.17(e) has been timely paid, the finality of the previous Office Action dated July 16, 2001 (Paper Number 8) has been withdrawn pursuant to 37 CFR §1.114.
- 2. Applicant's submission filed on September 15, 2003 has been entered.
- 3. Applicant's Preliminary Amendment filed September 15, 2003 has been received and entered.
- 4. Claims 1-13 have been cancelled.
- 5. Claims 14-24 have been added.
- 6. Claims 14-24 are examined on merits.
- 7. An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Charles A. Muserlian on 12/04/2003.

In the Claims:

In Claim 14 at Line five, the word "flavoneglycosides" has been omitted and replaced with the phrase -- flavone glycosides --.

In Claim 14 at Line 6, the word "proanthocyanidines" has been omitted and replaced with the word -- proanthocyanidins --.

In each of Claims 14 and 20, at line three after the first recitation of phrase, "human being", the phrase —in need thereof— has been inserted.

In each of Claims 14 and 20, at line three after the second recitation of phrase, "human being", the phrase "in need thereof" has been deleted.

In Claim 20 at line six, the word "flavoneglycosides" has been omitted and replaced with the phrase -- flavone glycosides --.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Kailash C. Srivastava whose telephone number is (703) 605-1196. The

examiner can normally be reached on Monday to Thursday from 7:30 A.M. to 6:00 P.M. (Eastern Standard or Daylight Savings Time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743 Monday through Thursday. The fax phone number for the organization where this application or proceeding is assigned is (703)-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Kallash C. Srivastava, Ph.D. Patent Examiner
Art Unit 1651
(703) 605-1196

December 8, 2003

CHRISTOPHER R.TATE PRIMARY EXAMINER